ライフサイエンスコーパス: bioreductive

1 d and evaluated for their ability to undergo bioreductive activation by reductase enzymes under oxyge

2 odrug of the nitroimidazole class, requiring bioreductive activation of an aromatic nitro group to ex

3 might interact with enzymes involved in the bioreductive activation of this drug.

4 (P)H:quinone oxidoreductase (DT-diaphorase), bioreductive activation to DNA-damaging species, and sel

5 DNA alkylation by AFs, mediated by bioreductive activation, is believed to contribute to cy

6 nyl)-1-(2-chloroethyl)hydrazine (90CE) after bioreductive activation.

7 eactive mitosene intermediate generated upon bioreductive activation.

8 prodrugs of phosphoramide mustard requiring bioreductive activation.

9 hypoxic tumor cells, following one-electron bioreductive activation.

10 Tirapazamine (TPZ) is a bioreductive agent that forms a toxic-free radical in hy

11 33, WIN 59075) is a benzotriazine-di-N-oxide bioreductive agent that is selectively activated to a re

12 (Sanofi Synthelabo Research, Malvern, PA), a bioreductive agent, in glioblastoma multiforme (GBM) pat

13 trials were run at our institution using the bioreductive alkylating agent mitomycin as an adjunct to

14 The bioreductive alkylating agent mitomycin is a safe and ef

15 cal data are presented supporting a proposed bioreductive alkylation mechanism of action.

16 d to an exemplar compound, CH-01, which is a bioreductive Chk1 inhibitor.

17 is compound might undergo hypoxia-selective, bioreductive conversion to the fluorescent product, 6-am

18 , mitomycin C (1) itself is the prototypical bioreductive DNA cross-linking agent.

19 y cellular reductases via a process known as bioreductive drug activation.

20 th an intelligent in silico model to measure bioreductive drug availability inside tumour tissue thro

21 Tirapazamine (TPZ) is a hypoxia-selective bioreductive drug currently in Phases II and III clinica

22 Tirapazamine (TPZ) is a bioreductive drug that exhibits greatly enhanced cytotox

23 ascular tumours, including the infusion of a bioreductive drug to study the effects of protein bindin

24 amine (TPZ) is the lead member of a class of bioreductive drugs currently in phase II and III clinica

25 To target this resistant population, bioreductive drugs that are preferentially toxic to tumo

26 efit of incorporating TPZ, and perhaps other bioreductive drugs, into a P450/P450 reductase-based gen

27 The two-electron bioreductive enzyme DT-diaphorase catalyzes the metaboli

28 that Trx provides reducing equivalents to a bioreductive enzyme for redox cycling of daunomycin.

29 he subcellular localization of overexpressed bioreductive enzyme NAD(P)H:quinone oxidoreductase 1 (NQ

30 To gain information on bioreductive enzymes involved in the activation of KS119

31 tibiotic mitomycin C is activated by several bioreductive enzymes, including DT-diaphorase.

32 We outline methods for attaching the bioreductive group to a range of functionalities, and we

33 Bioreductive in situ treatment of U-contaminated groundw

34 r investigation of the complexes suggested a bioreductive mechanism causing intracellular release of

35 D(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-(allylamino)-demethoxygeld

36 Bioreductive metabolism of nitroaryl compounds represent

37 these diflavin oxidoreductases also enhanced bioreductive metabolism of PR-104A in an anoxia-specific

38 The mono-N-oxide (3) stemming from bioreductive metabolism of tirapazamine converts the C1'

39 10 years of study, the products arising from bioreductive metabolism of tirapazamine have not been co

40 Bioreductive metabolism studies of selected model sulfox

41 eduction and, therefore, is found as a major bioreductive metabolite under all conditions.

42 eviously reported racemic mixtures of chiral bioreductive phosphoramidate prodrugs.

43 d 24-fold selectivity as a hypoxia-selective bioreductive prodrug, with an IC50 value of 2 microM aga

44 easing biological relevance, to validate the bioreductive prodrug.

45 e dissociation of vehicles and activation of bioreductive prodrugs simultaneously.

46 ompound delivery to hypoxic regions by using bioreductive prodrugs.

47 hyl-2-nitro-1H-imidazole-based precursors of bioreductive prodrugs.

48 Without AQDS, bioreductive solubilization was slower ( approximately 2

49 A facile bioreductive synthesis is described for Au nanoparticles